Paradigm Biopharmaceuticals Limited.. (ASX:PAR)

$1.52

right-arrow Created with Sketch. -0.05 (-3.19%)
MCAP $363.5M
Last trade 16.10pm 24/01/2022 20mins delayed

Latest Announcements

13/01/2022 Price SensitivePSPARParadigm Biopharmaceuticals Limited..
12/01/2022PARParadigm Biopharmaceuticals Limited..
24/12/2021PARParadigm Biopharmaceuticals Limited..
16/12/2021 Price SensitivePSPARParadigm Biopharmaceuticals Limited..
02/12/2021PARParadigm Biopharmaceuticals Limited..
30/11/2021PARParadigm Biopharmaceuticals Limited..
24/11/2021PARParadigm Biopharmaceuticals Limited..
23/11/2021 Price SensitivePSPARParadigm Biopharmaceuticals Limited..

Company Overview

Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company is developing and commercializing injectable Pentosan Polysulfate Sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The Company focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), chronic heart failure (CHF) and alphaviral arthritis (Ross River Virus and Chikungunya). Its product candidate PPS is a non-opioid drug treatment for the chronic pain and joint stiffness of Osteoarthritis. Its product candidate PPS is providing treatment for Mucopolysaccharidosis, an inherited defect in the catabolism of sulfated components of connective tissue known as glycosaminoglycans (GAGs). Its product candidate PPS is used to treat Ross River virus and Chikungunya, an arthritogenic alphaviruses transmitted by mosquito bites.

PAR in the news

Paradigm Biopharmaceuticals (PAR) doses its first two subjects with Zilosul in its…
Paradigm Biopharmaceuticals (PAR) says it has received positive interim data from a…
Paradigm Biopharmaceuticals (PAR) sees a shake up to its leadership board, with…
Paradigm Biopharmaceuticals (PAR) has had its investigational new drug application cleared to…

Search Previous Announcements